Former OpenAI science chief launches drug startup with $215 million

Kevin Weil, the former OpenAI executive who led its AI-for-science work, has started a new company called Warp Sciences. It came out of stealth on Thursday with $215 million in funding. Stealth means a startup has worked quietly before telling the public what it does. The company wants to use artificial intelligence to speed up a key step of drug development.

What we know

Lightspeed led the funding round. IVP, Premji Invest and Lux Capital also invested. Warp says the round values the company at $865 million after the new money. That figure is the price investors put on the company, not proof that it works.

Weil previously led the ChatGPT maker's efforts to apply AI to science. Warp is his new venture in that same broad area, now aimed at medicine.

Why it matters

Developing a drug is slow. If AI can shorten even one important step, new treatments could reach patients sooner. That is the promise behind the company and behind the large sum investors put into it.

What is not known yet

The material available does not say which step of drug development Warp is targeting. It does not say how the technology works, which diseases it will focus on, or whether any medicine is in testing. There is also no word on a timeline.

For now, this startup has yet to prove it can speed anything up. The funding shows strong investor interest, but results will have to come from real work in the lab and with patients.